Brian L. Wilson
Brian L. Wilson
Stop FollowingBrian L. Wilson
View as an RSS Feed
View Brian L. Wilson's Articles BY TICKER:
AAPL,
ABIO,
ABT,
ACAD,
ACHN,
ACRX,
AEGR,
AEZS,
AFFY,
ALXA,
AMPE,
AMRN,
AMZN,
ANAC,
ANTH,
APPA.OB,
APPY,
ARAY,
ARIA,
ARNA,
ARQL,
ARRY,
ASTX,
ATHX,
ATRS,
AVEO,
BAC,
BBRY,
BCRX,
BHP,
BIIB,
BLRX,
BMRN,
C,
CBMX,
CELG,
CHTP,
CLDX,
CLSN,
CORT,
CPRX,
CRME,
CUR,
CVM,
CYCC,
CYNO,
CYTK,
DARA,
DCTH,
DIS,
DMPI.OB,
DNDN,
DSCO,
DVAX,
EDAP,
EXEL,
F,
FOLD,
FRX,
FURX,
GALT,
GE,
GSK,
GWAY,
HALO,
HPTX,
HZNP,
IBM,
IMGN,
INO,
INTC,
ISIS,
ITMN,
JNJ,
JPM,
KERX,
KO,
LLY,
LNG,
LON,
LPTN,
LXRX,
MAKO,
MDVN,
MNKD,
MRK,
MSLP.OB,
MYRX,
NAVB,
NPSP,
NSPH,
NVS,
OMER,
ONCY,
ONXX,
OPXA,
ORCL,
OREX,
OSIR,
OSUR,
OXY,
PCRX,
PCYC,
PFE,
PGNX,
PPHM,
PTN,
QCOR,
REGN,
RIGL,
RMTI,
RPRX,
RPTP,
SCMP,
SDRL,
SGMO,
SKUL,
SLV,
SNGX.OB,
SPPI,
SPY,
SRPT,
STML,
STXS,
SUPN,
T,
THRX,
TKMR,
TLON.OB,
TTNP.OB,
VRTX,
VVUS,
WMT,
ZGNX,
ZIOP
- Promising RNA Company Tekmira Ready To Release Data At AACR 2013
- Tecfidera Raises The Bar For Biogen Idec
- Repros Moves Up On Phase III Data, Both Co-Endpoints Met
- Ziopharm's Palifosfamide Fails Its Soft Tissue Cancer Indication, NSCLC Next?
- Anacor Rallies On AN2728 Progress And Market Attention
- Is Acadia An Acquisition Target?
- Supernus: Record For Worst Launch In Recent History?
- Halozyme Rallies On Success In Europe, US Next Target
- Why Amarin Is Struggling So Much
- Piper Jaffray Likes Array, Should You?
- Dendreon: Potentially Heading To $2/Share By 2016?
- 2 Biopharma Stocks Rallying On Fresh Clinical Trial Data
- Neuralstem Update Fails To Excite, All Eyes On Upcoming Phase II Trial
- Titan Shares Stay Depressed Over FDA Approval Concerns
- Strong Relistor Sales Drive New Rally In Progenics
- A Likely Turnaround And Short Squeeze For Navidea Shares
- Fusilev Unravels Spectrum's Revenue Growth, Bears Descend On Company
- Big Move To Occur In Sarepta Therapeutics
- Did We Overestimate The Size Of The Obesity Drug Space?
- What's Going On With Celldex?
- Peregrine Releases Earnings, But The Situation Remains The Same
- 3 Med Device Stocks Looking Very Attractive
- For Onyx Investors, Long Term Value Collides With Short Term Uncertainty
- After FDA Approval, A New And Bigger Catalyst Looms Closer For Immunogen
- Can Dendreon Shareholders Avoid Dilution?
- Questcor: A Possible 30% Upside, If Not More, Before 2014
- Delcath Drifts 30% Higher On PDUFA Anticipation
- Is Affymax A Knife Worth Catching?
- Amarin: Is The Trend Still Your Friend?
- Osiris Wows The Market With Stellar Earnings Report
- Investors Seeing Huge Potential In RNA Drug Developers
- Buyout Speculation Drives Up Theravance Ahead Of FDA Advisory Committee Meeting